Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basmisanil in children with Dup15q syndrome
2021-003791-13Phase 2Terminated
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dup15q syndrome comparing basmisanil with placebo (2 arms). Primary endpoint: Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) Adaptive Behavior Composite. Started Oct 2021; status: terminated.
02
Drugs
basmisanil
03
Conditions
dup15q syndrome
Beyond the preview
Go deeper on 2021-003791-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003791-13.